Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Polack, FP; Thomas, SJ; Kitchin, N; Absalon, J; Gurtman, A; Lockhart, S; Perez, JL; Marc, GP; Moreira, ED; Zerbini, C; et al.
New England Journal of Medicine.
2020;
383:2603-2615.
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
Walsh, EE; Frenck, RW; Falsey, AR; Kitchin, N; Absalon, J; Gurtman, A; Lockhart, S; Neuzil, K; Mulligan, MJ; Bailey, R; et al.
New England Journal of Medicine.
2020;
383:2439-2450.
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.
Mulligan, MJ; Lyke, KE; Kitchin, N; Absalon, J; Gurtman, A; Lockhart, S; Neuzil, K; Raabe, V; Bailey, R; Swanson, KA; et al.
Nature: New biology.
2020;
586:589-593.
Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G.
Clarkson, KA; Frenck, RW; Dickey, M; Suvarnapunya, AE; Chandrasekaran, L; Weerts, HP; Heaney, CD; McNeal, M; Detizio, K; Parker, S; et al.
mSphere.
2020;
5.
Establishment of a Controlled Human Infection Model with a Lyophilized Strain of Shigella sonnei 53G.
Frenck, RW; Dickey, M; Suvarnapunya, AE; Chandrasekaran, L; Kaminski, RW; Clarkson, KA; McNeal, M; Lynen, A; Parker, S; Hoeper, A; et al.
mSphere.
2020;
5.
Warp Speed for COVID-19 Vaccines: Why are Children Stuck in Neutral?.
Anderson, EJ; Campbell, JD; Creech, CB; Frenck, R; Kamidani, S; Munoz, FM; Nachman, S; Spearman, P.
Clinical Infectious Diseases.
2020.
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study.
Walsh, EE; Frenck, R; Falsey, AR; Kitchin, N; Absalon, J; Gurtman, A; Lockhart, S; Neuzil, K; Mulligan, MJ; Bailey, R; et al.
2020.
Hospital-acquired Pneumonia and Ventilator-associated Pneumonia in Children: A Prospective Natural History and Case-Control Study.
Ericson, JE; McGuire, J; Michaels, MG; Schwarz, A; Frenck, R; Deville, JG; Agarwal, S; Bressler, AM; Gao, J; Spears, T; et al.
Pediatric Infectious Disease Journal.
2020;
39:658-664.
Third human challenge trial conference, Oxford, United Kingdom, February 6-7, 2020, a meeting report.
Pollard, AJ; Sauerwein, R; Baay, M; Neels, P; Balasingam, S; Bejon, P; Berthels, N; Bull, S; Catchpole, A; Chi, P; et al.
(2020)
66:41-52.
Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag).
Creech, CB; Frenck, RW; Fiquet, A; Feldman, R; Kankam, MK; Pathirana, S; Baber, J; Radley, D; Cooper, D; Eiden, J; et al.
Open Forum Infectious Diseases.
2020;
7.